<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>There have been only 3 positive Phase III randomized clinical trials in <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo>, <z:hpo ids='HP_0000001'>all</z:hpo> reperfusion therapies (NINDS; PROACT II; ECASS III) </plain></SENT>
<SENT sid="1" pm="."><plain>The only approved <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> therapy is &lt;3-hour IV tPA </plain></SENT>
<SENT sid="2" pm="."><plain>Although numerous compounds have shown benefit in animal models of <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e>, there has never been a positive Phase III randomized clinical trial of a neuroprotectant in <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>There are many challenges to <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> clinical trials but chief among these are the very short therapeutic window ("time is brain") and the issue of <z:hpo ids='HP_0001297'>stroke</z:hpo> <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0001297'>Stroke</z:hpo> is a syndrome and only a very small percentage of <z:hpo ids='HP_0000001'>all</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> patients present to hospitals in time to consider reperfusion therapy </plain></SENT>
<SENT sid="5" pm="."><plain>Many drugs have been rushed to trial prematurely based on inadequate preclinical testing </plain></SENT>
<SENT sid="6" pm="."><plain>Many trials have been seriously underpowered due to overly optimistic treatment expectations and the risk of brain <z:mp ids='MP_0001914'>hemorrhage</z:mp> has precluded aggressive multimodal treatment strategies </plain></SENT>
<SENT sid="7" pm="."><plain>Rather than simply relying on a clock, new imaging methods are being developed to identify patients with "tissue at risk" and "salvageable brain" regardless of time of <z:hpo ids='HP_0001297'>stroke</z:hpo> <z:hpo ids='HP_0003674'>onset</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>The 7 STAIR conferences have been convened to address these and other challenges to <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> trial design and completion </plain></SENT>
</text></document>